Autor: |
M. Elmer, A. R. Martin, J. D. Pearson, B. Cai, Steven M. Grunberg, Alexandra D. Carides, Sant P. Chawla, C. Schmidt, Kevin J. Horgan |
Rok vydání: |
2003 |
Předmět: |
|
Zdroj: |
European Journal of Cancer. 39:1395-1401 |
ISSN: |
0959-8049 |
Popis: |
Little information exists on the functional impact of effective antiemetic protection. In the present study, the Functional Living Index-Emesis (FLIE), was used to assess patient-reported impact of chemotherapy-induced nausea and vomiting (CINV) after administration of a new NK-1 receptor antagonist (aprepitant). Cisplatin-treated patients in a double-blind randomised trial received either aprepitant+dexamethasone+ondansetron on day 1 and aprepitant+dexamethasone on days 2-5 or standard antiemetic therapy (dexamethasone and ondansetron on day 1 and dexamethasone on days 2-5). Emetic events, nausea ratings and rescue medications were recorded in a 5-day diary and the FLIE was completed on day 6. Compared with standard therapy, significantly more patients treated with the high dose aprepitant regimen achieved a Complete Response (71 vs 44%, P |
Databáze: |
OpenAIRE |
Externí odkaz: |
|